Novo Nordisk’s Q4 performance was in line with our expectations, although downward revision of long-term growth expectation and waning forex benefit weighed on the stock. The share price plunged 7% on 3 February when the results were announced and, aggravated by sector volatility, has lost another 10% since then (as of 8 February). Sales for the quarter grew by 8% in LC and 17% in DKK to DKK29.9bn, led by Victoza (+10% in LC and 22% in DKK), Levemir (+22% in LC and 34% in DKK) and healt
09 Feb 2016
Results strong but market perturbed by lower guidance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Results strong but market perturbed by lower guidance
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
09 Feb 2016 -
Author:
Kamla Singh -
Pages:
3
Novo Nordisk’s Q4 performance was in line with our expectations, although downward revision of long-term growth expectation and waning forex benefit weighed on the stock. The share price plunged 7% on 3 February when the results were announced and, aggravated by sector volatility, has lost another 10% since then (as of 8 February). Sales for the quarter grew by 8% in LC and 17% in DKK to DKK29.9bn, led by Victoza (+10% in LC and 22% in DKK), Levemir (+22% in LC and 34% in DKK) and healt